Gemphire Therapeutics
Pharmaceutical ManufacturingMichigan, United States11-50 Employees
Gemphire is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. We are developing our product candidate gemcabene (CI 1027), a novel, once daily, oral therapy, for patients who are unable to achieve normal levels of LDL C or triglycerides with currently approved therapies, primarily statin therapy. Gemcabene’s mechanism of action is designed to enhance the clearance of very low density lipoproteins (VLDLs) in the plasma and inhibit the production of fatty acids and cholesterol in the liver. The Gemphire team is also exploring the utility of gemcabene in Nonalcoholic Steatohepatitis (NASH) and/or Nonalcoholic Fatty Liver Disease (NAFLD) given its mechanism of action that decreases the production of the apoC III protein and may inhibit ACC, which has been observed to result in the lowering of triglycerides in the plasma and may reduce liver fat. We are focused on a broad spectrum of indications for dyslipidemia patients ranging from the orphan indication HoFH to more prevalent conditions, such as HeFH, ASCVD and SHTG. In the next twelve months, we plan to initiate three late stage clinical trials with early results expected starting at the end of 2016 continuing through the first half of 2018.
1-888-653-2347 
support@leadiq.com 
